Compare WGO & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | ANNX |
|---|---|---|
| Founded | 1958 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.0M | 726.1M |
| IPO Year | 1994 | 2020 |
| Metric | WGO | ANNX |
|---|---|---|
| Price | $31.32 | $4.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $35.57 | $17.00 |
| AVG Volume (30 Days) | 930.7K | ★ 3.6M |
| Earning Date | 12-18-2026 | 11-17-2026 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | ★ 32.97 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $1,985,674,000.00 | N/A |
| Revenue This Year | $0.00 | N/A |
| Revenue Next Year | $5.17 | N/A |
| P/E Ratio | $28.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.95 | $2.54 |
| 52 Week High | $50.16 | $7.18 |
| Indicator | WGO | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 54.86 |
| Support Level | $27.54 | $3.71 |
| Resistance Level | $31.79 | $4.37 |
| Average True Range (ATR) | 1.76 | 0.26 |
| MACD | 0.68 | 0.06 |
| Stochastic Oscillator | 71.53 | 65.34 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2010 with the acquisition of SunnyBrook and acquired Grand Design in 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in 2019, and acquired Barletta pontoon boats in 2021. It also is developing electric and autonomous technology.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.